KaloBios (KBIO) Surge Continues As Firm Names Martin Shkreli As New CEO

Mani

Published onNovember 23, 2015

Updated on May 13, 2021

KaloBios Pharmaceuticals announced late Thursday that former hedge fund manager Martin Shkreli has become its chief executive officer and chairman after he led a group of investors to buy 70% of the drug developer’s outstanding shares, or as DealBreaker so eloquently put it ” Desperate Pharmaceutical Company Hits Rock Bottom, Names Martin Shkreli CEO“- The South San Francisco-based company said Shkreli will work with KalioBios’ senior management team to ensure its continued operations.

Table of Contents

Shkreli’s majority stake in KaloBios

As outlined by ValueWalk, a regulatory filing with the Securities and Exchange Commission revealed that Shkreli...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

KaloBios (KBIO) Surge Continues As Firm Names Martin Shkreli As New CEO

Shkreli’s majority stake in KaloBios

Login required to continue reading.

Get Your Business News